A Randomized, Placebo-Controlled Phase II Study to Compare the Efficacy and Safety of SU011248 [sunitinib] Versus Placebo in Patients With Advanced Urothelial Transitional Cell Carcinoma Who Have Failed or Are Intolerant to Cisplatin-Based Chemotherapy.

Trial Profile

A Randomized, Placebo-Controlled Phase II Study to Compare the Efficacy and Safety of SU011248 [sunitinib] Versus Placebo in Patients With Advanced Urothelial Transitional Cell Carcinoma Who Have Failed or Are Intolerant to Cisplatin-Based Chemotherapy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms SPRUCE
  • Most Recent Events

    • 18 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 20 Nov 2009 Actual initiation date (1 Apr 2008) added as reported by ClinicalTrials.gov.
    • 20 Nov 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top